Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $2,532,177 | $1,716,022 | $2,021,171 | $2,135,123 |
| - Cash | $112,724 | $96,648 | $175,787 | $94,819 |
| + Debt | $0 | $72,446 | $72,368 | $72,453 |
| Enterprise Value | $2,419,453 | $1,691,820 | $1,917,752 | $2,112,757 |
| Revenue | $118,697 | $102,660 | $78,335 | $66,408 |
| % Growth | 15.6% | 31.1% | 18% | – |
| Gross Profit | $94,104 | $96,423 | $73,124 | $61,482 |
| % Margin | 79.3% | 93.9% | 93.3% | 92.6% |
| EBITDA | -$12,125 | -$17,647 | -$22,447 | -$20,369 |
| % Margin | -10.2% | -17.2% | -28.7% | -30.7% |
| Net Income | -$12,585 | -$20,340 | -$25,120 | -$23,113 |
| % Margin | -10.6% | -19.8% | -32.1% | -34.8% |
| EPS Diluted | -0.3 | -0.48 | -0.64 | -0.6 |
| % Growth | 37.5% | 25% | -6.7% | – |
| Operating Cash Flow | $18,257 | -$29,387 | -$20,651 | -$22,182 |
| Capital Expenditures | -$1,910 | -$1,001 | -$590 | -$5,072 |
| Free Cash Flow | $16,347 | -$30,388 | -$21,241 | -$27,254 |